MUFG Securities EMEA plc Purchases New Holdings in Humana Inc. (NYSE:HUM)

MUFG Securities EMEA plc purchased a new stake in shares of Humana Inc. (NYSE:HUM) in the first quarter, Holdings Channel reports. The firm purchased 36,999 shares of the insurance provider’s stock, valued at approximately $9,790,000.

A number of other institutional investors and hedge funds also recently modified their holdings of HUM. Vanguard Group Inc. grew its holdings in Humana by 8.9% during the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock valued at $3,697,222,000 after purchasing an additional 1,143,662 shares during the period. Dodge & Cox grew its holdings in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after purchasing an additional 5,264,045 shares during the period. Pzena Investment Management LLC grew its holdings in Humana by 6.1% during the first quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider’s stock valued at $1,013,133,000 after purchasing an additional 219,541 shares during the period. Davis Selected Advisers grew its holdings in Humana by 3.3% during the first quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider’s stock valued at $616,873,000 after purchasing an additional 74,434 shares during the period. Finally, T. Rowe Price Investment Management Inc. grew its holdings in Humana by 11.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,605,771 shares of the insurance provider’s stock valued at $407,401,000 after purchasing an additional 160,952 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HUM. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Raymond James Financial raised Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price objective for the company in a report on Thursday, May 1st. Wall Street Zen lowered Humana from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Barclays set a $275.00 price target on Humana and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Finally, Oppenheimer raised their price target on Humana from $300.00 to $310.00 and gave the stock an “outperform” rating in a report on Thursday, May 1st. Seventeen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $281.62.

Humana Trading Up 4.1%

Shares of HUM stock opened at $266.65 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The business’s fifty day moving average is $237.88 and its 200 day moving average is $254.38. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $382.72. The company has a market capitalization of $32.07 billion, a PE ratio of 20.46, a price-to-earnings-growth ratio of 1.51 and a beta of 0.44.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. Humana’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the company posted $6.96 earnings per share. On average, equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.